AbbVie [ABBV] vs Gilead Sciences [GILD] Detailed Stock Comparison
AbbVie
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: AbbVie wins in 8 metrics, Gilead Sciences wins in 12 metrics, with 0 ties. Gilead Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | AbbVie | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 104.87 | 22.73 | Gilead Sciences |
| Price-to-Book Ratio | -2,797.28 | 7.23 | AbbVie |
| Debt-to-Equity Ratio | -511.49 | 127.34 | AbbVie |
| PEG Ratio | -3.23 | 1.05 | AbbVie |
| EV/EBITDA | 15.60 | 11.66 | Gilead Sciences |
| Profit Margin (TTM) | 6.45% | 21.87% | Gilead Sciences |
| Operating Margin (TTM) | 37.52% | 39.16% | Gilead Sciences |
| EBITDA Margin (TTM) | 37.52% | 39.16% | Gilead Sciences |
| Return on Equity | 112.85% | 33.40% | AbbVie |
| Return on Assets (TTM) | 8.87% | 12.62% | Gilead Sciences |
| Free Cash Flow (TTM) | $17.83B | $10.31B | AbbVie |
| Dividend Yield | 3.44% | 3.25% | AbbVie |
| 1-Year Return | 12.41% | 38.33% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 6.67 | 4.92 | Gilead Sciences |
| Enterprise Value | $438.04B | $160.94B | AbbVie |
| EV/Revenue Ratio | 7.51 | 5.58 | Gilead Sciences |
| Gross Profit Margin (TTM) | 71.82% | 78.80% | Gilead Sciences |
| Revenue per Share (TTM) | $33 | $23 | AbbVie |
| Earnings per Share (Diluted) | $2.10 | $5.04 | Gilead Sciences |
| Beta (Stock Volatility) | 0.53 | 0.38 | Gilead Sciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
AbbVie vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| AbbVie | -0.85% | 2.72% | 9.92% | 13.47% | 2.96% | 21.68% |
| Gilead Sciences | -2.81% | -0.43% | -4.56% | 2.23% | 0.49% | 24.67% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| AbbVie | 12.41% | 51.55% | 142.28% | 256.62% | 561.58% | 561.58% |
| Gilead Sciences | 38.33% | 74.62% | 76.10% | 5.63% | 562.91% | 889.21% |
News Based Sentiment: AbbVie vs Gilead Sciences
AbbVie
News based Sentiment: POSITIVE
September was a pivotal month for AbbVie, primarily driven by the successful patent settlement for Rinvoq, which significantly extends market exclusivity and boosts future revenue potential. This, combined with positive clinical trial data and strategic acquisitions, strengthens the company's long-term growth trajectory and reinforces its position as a compelling investment.
Gilead Sciences
News based Sentiment: MIXED
Gilead reported strong Q2 results and is making significant investments in manufacturing and HIV prevention, signaling growth potential. However, continued insider selling and mixed analyst sentiment introduce uncertainty, creating a complex investment picture. The combination of positive financial performance and strategic initiatives alongside these concerns warrants a 'mixed' assessment.
Performance & Financial Health Analysis: AbbVie vs Gilead Sciences
| Metric | ABBV | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $385.71B | $142.13B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 4,431,696 | 6,749,120 |
| 90 Day Avg. Volume | 4,744,749 | 6,467,877 |
| Last Close | $218.34 | $114.55 |
| 52 Week Range | $163.81 - $221.77 | $81.57 - $121.83 |
| % from 52W High | -1.55% | -5.98% |
| All-Time High | $221.77 (Sep 11, 2025) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -1.55% | -7.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.02% |
| Quarterly Earnings Growth | -0.32% | 0.21% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.22% |
| Operating Margin (TTM) | 0.38% | 0.39% |
| Return on Equity (TTM) | 1.13% | 0.33% |
| Debt to Equity (MRQ) | -511.49 | 127.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-0.10 | $15.84 |
| Cash per Share (MRQ) | $3.66 | $4.88 |
| Operating Cash Flow (TTM) | $19.28B | $9.87B |
| Levered Free Cash Flow (TTM) | $20.04B | $8.84B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.44% | 3.25% |
| Last 12-Month Dividend | $6.38 | $3.91 |
Valuation & Enterprise Metrics Analysis: AbbVie vs Gilead Sciences
| Metric | ABBV | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 104.87 | 22.73 |
| Forward P/E | 18.15 | 15.42 |
| PEG Ratio | -3.23 | 1.05 |
| Price to Sales (TTM) | 6.67 | 4.92 |
| Price to Book (MRQ) | -2,797.28 | 7.23 |
| Market Capitalization | ||
| Market Capitalization | $385.71B | $142.13B |
| Enterprise Value | $438.04B | $160.94B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.51 | 5.58 |
| Enterprise to EBITDA | 15.60 | 11.66 |
| Risk & Other Metrics | ||
| Beta | 0.53 | 0.38 |
| Book Value per Share (MRQ) | $-0.10 | $15.84 |
Financial Statements Comparison: AbbVie vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ABBV | GILD |
|---|---|---|
| Revenue/Sales | $13.34B | $6.67B |
| Cost of Goods Sold | $4.00B | $1.54B |
| Gross Profit | $9.34B | $5.13B |
| Research & Development | $2.07B | $1.38B |
| Operating Income (EBIT) | $3.98B | $2.49B |
| EBITDA | $4.65B | $3.28B |
| Pre-Tax Income | $1.66B | $1.65B |
| Income Tax | $372.00M | $334.00M |
| Net Income (Profit) | $1.29B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ABBV | GILD |
|---|---|---|
| Cash & Equivalents | $5.18B | $7.93B |
| Total Current Assets | $27.68B | $16.90B |
| Total Current Liabilities | $36.40B | $12.34B |
| Long-Term Debt | $64.53B | $22.15B |
| Total Shareholders Equity | $1.46B | $19.08B |
| Retained Earnings | $-9.53B | $10.93B |
| Property, Plant & Equipment | N/A | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ABBV | GILD |
|---|---|---|
| Operating Cash Flow | $2.26B | $1.56B |
| Capital Expenditures | $-235.00M | $-104.00M |
| Free Cash Flow | $1.40B | $1.65B |
| Debt Repayment | $-3.03B | $-1.76B |
| Common Stock Repurchase | $-961.00M | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | ABBV | GILD |
|---|---|---|
| Shares Short | 15.40M | 17.56M |
| Short Ratio | 3.12 | 2.79 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 4,431,696 | 6,749,120 |
| Average Daily Volume (90 Day) | 4,744,749 | 6,467,877 |
| Shares Outstanding | 1.77B | 1.25B |
| Float Shares | 1.76B | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.75% | 0.91% |
Dividend Analysis & Yield Comparison: AbbVie vs Gilead Sciences
| Metric | ABBV | GILD |
|---|---|---|
| Last 12-Month Dividend | $6.38 | $3.91 |
| Last 12-Month Dividend Yield | 3.44% | 3.25% |
| 3-Year Avg Annual Dividend | $6.07 | $3.30 |
| 3-Year Avg Dividend Yield | 0.95% | 0.91% |
| 3-Year Total Dividends | $18.22 | $9.91 |
| Ex-Dividend Date | Apr 15, 2025 | Sep 15, 2025 |